Limits...
Drug policy down under: Australia's pharmaceutical benefits scheme.

Duckett SJ - Health Care Financ Rev (2004)

Bottom Line: The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950.It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries).Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis.

View Article: PubMed Central - PubMed

Affiliation: La Trobe University, Victoria, Australia. sduckett@latrobe.edu.au

ABSTRACT
Australia has had a government subsidized universal system of pharmaceutical provision for 50 years. The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950. It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries). Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis.

Show MeSH
Ratio of Prevailing Prices for Pharmaceuticals in Selected Countries in Comparison to Australia's1 Pharmaceutical Benefits Scheme: 20001 PBS equals 1.0. NOTE: Me-too pharmaceuticals are pharmaceuticals for which an alternative is already available.SOURCE: (Productivity Commission, 2001.)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4194861&req=5

f2-hcfr-25-3-055: Ratio of Prevailing Prices for Pharmaceuticals in Selected Countries in Comparison to Australia's1 Pharmaceutical Benefits Scheme: 20001 PBS equals 1.0. NOTE: Me-too pharmaceuticals are pharmaceuticals for which an alternative is already available.SOURCE: (Productivity Commission, 2001.)

Mentions: International comparison of pricing is difficult, in part because of the existence of discounting arrangements in several countries: list prices may not reflect prices actually paid in the market place (Productivity Commission, 2001). Accordingly, in its major study of comparative prices of drugs, the Productivity Commission reported high and low estimates of the difference between costs in other countries and costs in Australia (Figure 2). The high estimate is the greatest difference likely to be found.


Drug policy down under: Australia's pharmaceutical benefits scheme.

Duckett SJ - Health Care Financ Rev (2004)

Ratio of Prevailing Prices for Pharmaceuticals in Selected Countries in Comparison to Australia's1 Pharmaceutical Benefits Scheme: 20001 PBS equals 1.0. NOTE: Me-too pharmaceuticals are pharmaceuticals for which an alternative is already available.SOURCE: (Productivity Commission, 2001.)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4194861&req=5

f2-hcfr-25-3-055: Ratio of Prevailing Prices for Pharmaceuticals in Selected Countries in Comparison to Australia's1 Pharmaceutical Benefits Scheme: 20001 PBS equals 1.0. NOTE: Me-too pharmaceuticals are pharmaceuticals for which an alternative is already available.SOURCE: (Productivity Commission, 2001.)
Mentions: International comparison of pricing is difficult, in part because of the existence of discounting arrangements in several countries: list prices may not reflect prices actually paid in the market place (Productivity Commission, 2001). Accordingly, in its major study of comparative prices of drugs, the Productivity Commission reported high and low estimates of the difference between costs in other countries and costs in Australia (Figure 2). The high estimate is the greatest difference likely to be found.

Bottom Line: The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950.It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries).Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis.

View Article: PubMed Central - PubMed

Affiliation: La Trobe University, Victoria, Australia. sduckett@latrobe.edu.au

ABSTRACT
Australia has had a government subsidized universal system of pharmaceutical provision for 50 years. The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950. It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries). Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis.

Show MeSH